
Data from patients with eGFR of 20 mL/min/1.73m2 or less from the ADVOCATE trial provide new insight into the effects of avacopan use in patients with lower baseline eGFRs.

Data from patients with eGFR of 20 mL/min/1.73m2 or less from the ADVOCATE trial provide new insight into the effects of avacopan use in patients with lower baseline eGFRs.

An analysis of national data shows Asian and male patients are at worse risk of mortality, however.

An analysis of more than 1 million AFib hospitalizations suggests those with large vessel vasculitis had a nearly 2-fold increase in risk of acute myocardial infarction and a more than 9-fold increase in risk of acute kidney injury.